Muscle Glycogenoses

  • N. Kono
  • S. Tarui


In some glycogen storage disease of the muscles, particularly muscle phosphorylase deficiency (GSD type V), the impaired glycogen degradation causes exercise interolerance. This is associated with muscle stiffness, weakness, and pain on exertion. Semi-ischemic forearm exercise or bicycle ergometer exercise discloses no elevation of the venous lactate level, but marked increases of serum creatine kinase, ammonia, inosine, and hypoxanthine. These purine metabolites serve as substrates for the synthesis of uric acid, leading to hyperuricemia (myogenic hyperuricemia). In GSD type V glucagon administration augments exercise tolerance and exercise-induced lactate production by muscles. Administration of glucose or glucose plus insulin causes similar beneficial effects. The “second wind” phenomenon occurs frequently in GSD type V. Oral administration of coenzyme Q10 improves the exercise tolerance, at least subjectively.

In glycolysis defects in muscles, similar muscular symptoms appear and the serum creatine kinase level increases. Myogenic hyperuricemia may occur. No beneficial effect of glucagon treatment has been reported.

Mypopathy associated with increased hemolysis occurs in muscle phosphofructokinase deficiency (GSD type VII). Myogenic hyperuricemia develops. Neither a glucagon nor glucose effect is observed. Glucose tolerance is slightly impaired, and the “second wind” phenomenon occurs very rarely in GSD type VII.

Vigorous exercise should be avoided for every patient in each group of defects due to a risk of acute renal failure secondary to rhabdomyolysis (myoglobinuria) and of gout.


Acute Renal Failure Glycogen Storage Disease Enzyme Deficiency Triose Phosphate Isomerase Phosphoglycerate Mutase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mineo I, Kono N, Shimizu T, Sumi S, Nonaka K, Tarui S (1984) A comparative study on glucagon effect between McArdle disease and Tarui disease. Muscle Nerve 7: 552–559PubMedCrossRefGoogle Scholar
  2. 2.
    Mineo I, Kono N, Shimizu T et al. (1985) Excess purine degradation in exercising muscles of humans with glycogen storage disease types V and VII. J Clin Invest 76: 556–560PubMedCrossRefGoogle Scholar
  3. 3.
    Kono N, Mineo I, Tarui S (1987) Hyperuricemia in type V glycogenosis. Neurology 37: 729CrossRefGoogle Scholar
  4. 4.
    Mineo I, Kono N, Hara N et al. (1987) Myogenic hyperuricemia. A common pathophysiologic feature of glycogenosis types III, V and VII. N Engl J Med 317: 75–80PubMedCrossRefGoogle Scholar
  5. 5.
    Fox IH, Palella TD, Kelley WN (1987) Hyperuricemia: a marker for cell energy crisis. N Engl J Med 317: 111–112PubMedCrossRefGoogle Scholar
  6. 6.
    Pearson CM, Rimer DG, Mommaerts WFHM (1961) A metabolic myopathy due to absence of muscle phosphorylase. Am J Med 30: 502–517PubMedCrossRefGoogle Scholar
  7. 7.
    Tarui S, Mineo I, Shimizu T, Sumi S, Kono N (1984) Muscle phosphofructokinase deficiency and related disorders. In: Serratrice G et al. (eds) Neuromuscular diseases. Raven, New York, pp 71–77Google Scholar
  8. 8.
    Tabata T, Kikunami K, Matsushita Y et al. (1986) Acute renal failure in McArdle’s disease. Nephron 44: 371–374PubMedCrossRefGoogle Scholar
  9. 9.
    Tarui S, Kono N, Nasu T, Nishikawa M (1969) Enzymatic basis for the coexistence of myopathy and hemolytic disease in inherited muscle phosphofructokinase deficiency. Biochem Biophys Res Commun 34: 77–83PubMedCrossRefGoogle Scholar
  10. 10.
    Shimizu T, Kono N, Kiyokawa H et al. (1988) Erythrocyte glycolysis and its marked alteration by muscular exercise in type VII glycogenosis. Blood 71: 1130–1134PubMedGoogle Scholar
  11. 11.
    Kono N, Mineo I, Shimisu T et al. (1986) Increased plasma uric acid after exercise in muscle phosphofructokinase deficiency. Neurology 36: 106–108PubMedCrossRefGoogle Scholar
  12. 12.
    Rowland LP, Fahn S, Schotland DL (1963) McArdle’s disease: hereditary myopathy due to absence of muscle phosphorylase. Arch Neurol 9: 325–342PubMedCrossRefGoogle Scholar
  13. 13.
    Kono M, Mineo I, Sumi S et al. (1984) Metabolic basis of improved exercise tolerance: muscle phosphorylase deficiency after glucagon administration. Neurology 34: 1471–1476PubMedCrossRefGoogle Scholar
  14. 14.
    Viskoper RJ, Wolf E, Chaco J, Katz R, Chowers I (1975) McArdle’s syndrome: the reaction to a fat-rich diet. Am J Med Sci 269: 217–221PubMedCrossRefGoogle Scholar
  15. 15.
    Sugie H, Kobayashi J, Sugie Y et al. (1988) Infantile muscle glycogen storage disease: phosphoglucomutase deficiency with decreased muscle and serum carnitine levels. Neurology 38: 602–605PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • N. Kono
  • S. Tarui

There are no affiliations available

Personalised recommendations